TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Sutro Biopharma
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day

Sutro Biopharma announced the initiation of its Phase 1 study for STRO-004, a Tissue Factor ADC, and selected PTK7 as the target for its first dual-payload candidate STRO-227, showcasing its innovative antibody-drug conjugate platform.

Insights
STRO   positive

Company is advancing multiple promising ADC programs, entering clinical trials, and demonstrating platform innovation with potential to transform cancer treatment